A specific inhibitor of pSTAT6 (AS1517499) reduced cell viability in Mac1/2A cutaneous ALCL cell lines in a dose-dependent manner, as described previously for Sézary cells [82], indicating that blocking the IL-13/STAT6 signaling pathway may be a potential therapeutic regimen for SATB1+ CALCLs. This evidence concerns the gene STAT6 and anaplastic large cell lymphoma.